Swiss Biotech Stock News

Recently, ABB has seen elevated trading activity in pre-market sessions, supported by ongoing industrial demand and strong spending in robotics and electrification solutions. An interesting angle is that third-party AI-driven models are flagging medium-term growth opportunities for ABB, even as some valuation concerns remain. We’ll now examine how this renewed confidence in robotics and automation demand fits into, and potentially reshapes, ABB’s existing investment narrative. The future of...

Temenos (SWX:TEMN) is back in focus after reporting fourth quarter and full year 2025 results, with softer quarterly earnings but higher full year revenue and net income, prompting investors to reassess the stock. See our latest analysis for Temenos. Temenos shares trade at CHF64.2, with a 1 day share price return of 0.94% and a 7 day share price return of 1.82%. The 30 day share price return shows a 13.36% decline and the year to date share price return shows a 21.23% decline, while the 5...

If you are wondering whether Amrize is priced fairly or if there could be value on the table, this article will walk through what the current share price might be telling you. Amrize shares last closed at CHF 50.14, with returns of 13.7% over the past week, 16.7% over the past month and 12.7% year to date, which may have changed how investors view its potential and its risks. Recent attention around Amrize has prompted fresh interest in how the company is being valued, with investors looking...

Sika (SWX:SIKA) has agreed to acquire Turkey based adhesives and sealants manufacturer Akkim. The deal is part of Sika’s Strategy 2028 to expand its adhesives and sealants business globally. The planned transaction increases Sika’s production footprint and presence in high growth markets. Sika focuses on specialty chemicals for construction and industrial applications, and adhesives and sealants are a core part of that offering. By adding Akkim’s product range and manufacturing base in...

Belimo Holding (SWX:BEAN) has released its FY 2025 figures with second half revenue of CHF 559.3 million, basic EPS of CHF 6.54 and net income of CHF 80.4 million, while the trailing twelve month revenue sits at CHF 1.1 billion with EPS of CHF 14.77 and net income of CHF 181.6 million. The company has seen revenue move from CHF 470.3 million and EPS of CHF 5.65 in the second half of 2024 to CHF 561.5 million and EPS of CHF 8.23 in the first half of 2025, setting up this latest CHF 559.3...

If you are wondering whether Partners Group Holding is currently offering fair value or a potential opportunity, looking closely at its valuation can help put the recent share price in context. The stock closed at CHF 852.60, with returns of 9.6% decline over 7 days, 20.2% decline over 30 days, 17.2% decline year to date, 33.2% decline over 1 year, 7% return over 3 years and 11.2% decline over 5 years. These moves may have changed how the market views its risk and potential. Recent coverage...

Novartis has agreed to divest its majority stake in Novartis India Ltd. to a private equity led consortium, reshaping its footprint in the Indian market. • The company reported new late stage clinical results for remibrutinib in chronic urticaria and plans to present further data at a major allergy and immunology conference. These moves highlight a shift in focus toward its core medicines portfolio and immunology pipeline activity. For investors tracking SWX:NOVN, these updates come with...

PSP Swiss Property recently reported its 2025 results, with net income rising on property revaluations, a portfolio of about CHF 10.10 billion, and a proposed dividend increase to CHF 3.95 per share. An interesting angle is that the higher dividend comes even as underlying earnings softened, underscoring management’s reliance on revaluation gains and confidence in funding major redevelopment projects from a strong balance sheet. We’ll now examine how the higher dividend proposal, underpinned...

FDA filing for breast cancer drug puts Roche Holding (SWX:ROG) in focus Roche Holding (SWX:ROG) is back on investors’ radar after the U.S. FDA accepted its New Drug Application for giredestrant in ER positive, HER2 negative, ESR1 mutated advanced breast cancer. The filing, supported by phase III evERA Breast Cancer data, comes alongside positive readouts for Gazyva in kidney disease and constructive industry views on next generation sequencing and genetic testing, areas where Roche is an...

If you are wondering whether Nestlé shares still justify their price, you are not alone; the stock often attracts investors who care about what they are actually paying for each franc of underlying business. Nestlé shares last closed at CHF81.40, with returns of 1.5% over 7 days, 12.3% over 30 days, 6.5% year to date, and a 3.9% decline over 1 year, 17.8% decline over 3 years, and 3.3% decline over 5 years, hinting at changing views on its growth and risk profile. Recent headlines around...

Zug Estates Holding (SWX:ZUGN) drew fresh investor attention after reporting full year 2025 results, with revenue of CHF 91.5 million, net income of CHF 85.18 million, and an announced annual dividend of CHF 49 per share. See our latest analysis for Zug Estates Holding. The share price has climbed to CHF 2,400, with an 8.11% 1 month share price return and 11.63% 3 month share price return. The 1 year total shareholder return of 19.75% suggests momentum has been building over a longer...

If you are wondering whether Cosmo Pharmaceuticals at CHF116.20 is priced attractively or already baking in a lot of optimism, this article walks through what the numbers say about its value. The stock shows returns of 0.5% over 7 days, 1.8% over 30 days, 10.2% year to date, 76.5% over 1 year, 105.4% over 3 years and 53.4% over 5 years, which may prompt questions about how much of this performance is supported by fundamentals. Recent coverage has focused on Cosmo Pharmaceuticals' position...

SGS (SWX:SGSN) has just released full year 2025 results, reporting sales of CHF 6,945 million and net income of CHF 668 million, figures that suggest operational improvement compared with the prior year. See our latest analysis for SGS. SGS shares last closed at CHF94.2, and the stock has had a 90 day share price return of 4.88%, while the 1 year total shareholder return sits at 1.90%, with the 3 year total shareholder return at 20.65% and 5 year total shareholder return at 5.94%. This points...

Straumann Holding (SWX:STMN) announced an increase to its annual dividend alongside the release of its latest full year financial results. The new dividend level reflects the board's current capital allocation decision following the recent earnings announcement. This update adds a fresh data point for investors tracking the company's income profile and cash returns. Straumann Holding's latest dividend move comes after a challenging share price period, with the stock at CHF91.7 and showing a...

Sika (SWX:SIKA) is back in focus after recent share price moves that left the stock about 4.7% lower year to date, despite a roughly 5.8% gain over the past month. See our latest analysis for Sika. The recent 5.8% 30 day share price return contrasts with a year to date share price decline of about 4.7%. At the same time, the 1 year total shareholder return of roughly 31.8% and 5 year total shareholder return of about 32.7% signal fading longer term momentum. If this mixed picture has you...

Amrize (SWX:AMRZ) has drawn fresh attention after issuing upbeat 2026 revenue guidance, outlining both ordinary and special dividend proposals, and attracting supportive analyst commentary following its recent spin off. See our latest analysis for Amrize. After the guidance, dividend proposals and recent board and auditor changes, Amrize’s 7 day share price return of 9.34% and 90 day share price return of 20.79% suggest building positive momentum from a starting point of CHF49.15. If this has...

Alcon (SWX:ALC) is back in focus after the U.S. launch of its TOTAL30 Multifocal for Astigmatism contact lenses, a product aimed at presbyopic patients with astigmatism who have limited soft lens options. See our latest analysis for Alcon. The TOTAL30 Multifocal for Astigmatism launch comes as Alcon’s share price sits at CHF63.78, with a 7 day share price return of 6.1% but a 1 year total shareholder return decline of 20.6%, suggesting recent momentum contrasts with weaker longer term...

Belimo Holding (SWX:BEAN) reported full-year 2025 earnings with sales of CHF 1,120.81 million, net income of CHF 181.63 million, and basic EPS of CHF 14.77 from continuing operations. See our latest analysis for BELIMO Holding. The earnings release and cautious 2026 outlook have coincided with some pressure on the shares, with a 1-day share price return of a 10% decline and a 7-day share price return of a 6.3% decline. At the same time, the 1-year total shareholder return of 36.7% and 5-year...

Event driven repositioning at Partners Group Holding Partners Group Holding (SWX:PGHN) is in focus after shifting capital away from technology and software toward AI linked infrastructure assets, while its open ended private credit funds avoided net redemptions during recent sector volatility. See our latest analysis for Partners Group Holding. The recent repositioning toward AI linked infrastructure comes after a mixed run for investors, with a 30 day share price return of 14.25% decline, a...

Cembra Money Bank AG has already reported its full-year 2025 results, with net interest income of CHF 372.16 million and net income of CHF 179.57 million, and announced an annual dividend of CHF 4.60 per share, ex-date April 28, 2026. While net interest income eased slightly from the prior year, higher net income and an increased dividend highlight the bank’s ability to convert its lending activities into growing shareholder distributions. Next, we’ll examine how the higher net income and...

Why Novartis Stock Is On Investors’ Radar Today Novartis (SWX:NOVN) has drawn fresh attention after recent performance data showed a 9.9% return over the past month and 23% over the past 3 months, prompting investors to reassess its current valuation profile. See our latest analysis for Novartis. Beyond the recent jump, Novartis’ 16.55% year to date share price return and 33.45% one year total shareholder return suggest momentum has been building around its CHF126.46 share price and ongoing...

Nestlé (SWX:NESN) has set out a company wide shakeup, moving to sell its remaining ice cream assets, explore exits from vitamins and waters, and concentrate on coffee, petcare, nutrition, and food and snacks. See our latest analysis for Nestlé. These portfolio moves and the recent earnings update have come alongside a 10.55% 1 month share price return to CHF80.91. The 1 year total shareholder return of a 1.51% decline shows momentum has only recently started to improve after weaker multi year...

Sika (SWX:SIKA) has wrapped up FY 2025 with Q4 revenue of CHF 2.6b and net income of CHF 174.1m, while Q4 basic EPS came in at CHF 1.09. Over the past few quarters, the company has reported revenue of CHF 2.8b and EPS of CHF 2.02 in Q4 2024, CHF 2.9b in Q3 2025, and CHF 2.6b in Q4 2025. This sets up a results season where investors are likely to focus on how these changes in revenue and EPS relate to margins. See our full analysis for Sika. With the latest figures on the table, the next step...

EFG International (SWX:EFGN) has reported its FY 2025 results with second half revenue of CHF 864.5 million and basic EPS of CHF 0.34, alongside net income excluding extra items of CHF 112.8 million. The group has seen revenue move from CHF 753.4 million and basic EPS of CHF 0.49 in the second half of 2024 to CHF 793.8 million and basic EPS of CHF 0.71 in the first half of 2025. Trailing twelve month revenue of CHF 1.66 billion and basic EPS of CHF 1.03 set the broader context for today’s...